Introduction: There are dozens of drugs in development for AD with billions of dollars
invested. Despite the massive investment in AD drugs and a burgeoning pipeline, there …

Experimental models of Alzheimer's disease (AD) are critical to gaining a better
understanding of pathogenesis and to assess the potential of novel therapeutic approaches …

Neuropathological and in vivo studies have revealed a tight relationship between tau
pathology and cognitive impairment across the Alzheimer's disease spectrum. However, tau …

Accumulation of hyperphosphorylated tau directly correlates with cognitive decline in
Alzheimer's disease and other primary tauopathies. One therapeutic strategy may be to …

Alterations of the dopaminergic (DAergic) system are frequently reported in Alzheimer's
disease (AD) patients and are commonly linked to cognitive and non-cognitive symptoms …

Alzheimer's disease (AD) is characterized by severe neuronal loss; however, the
mechanisms by which neurons die remain elusive. Necroptosis, a programmed form of …

Abnormalities of the endosomal–lysosomal network (ELN) are a signature feature of
Alzheimer's disease (AD). These include the earliest known cytopathology that is specific to …

Alzheimer's disease (AD) affects an estimated 44 million individuals worldwide, yet no
therapeutic intervention is available to stop the progression of the dementia …

Lowering total tau levels is an attractive therapeutic strategy for Alzheimer's disease and
other tauopathies. High-throughput screening in neurons derived from human induced …

Background Neurofibrillary pathology composed of tau protein is a main correlate of
cognitive impairment in patients with Alzheimer's disease. Immunotherapy targeting …